What is WAVE Life Sciences?
WAVE Life Sciences is dedicated to advancing therapies for genetically defined diseases through its proprietary PRISM platform. This platform enables the precise design, optimization, and production of stereopure oligonucleotides, positioning the company at the forefront of genetic medicine innovation. The company's focus on developing best-in-class medicines across multiple therapeutic modalities highlights its commitment to addressing significant unmet medical needs.
How much funding has WAVE Life Sciences raised?
WAVE Life Sciences has raised a total of $451.3M across 5 funding rounds:
Multiple Rounds
$196M
Stock Offering
$93.5M
Stock Offering
$161.8M
Series A (2015): $18M with participation from Kagoshima Shinsangyo Sosei Investment, SNBL Ltd, and RA Capital Management
Series B (2015): $66M led by Foresite Capital, Redmile Group, Jennison Associates, RA Capital Management, Clough Capital Partners, Cormorant Asset Management, Fidelity Management Research Company, New Leaf Venture Partners, and Kagoshima Shinsangyo Sosei Investment
Stock Issuance/Offering (2015): $112M supported by Undisclosed
Stock Issuance/Offering (2017): $93.5M featuring Undisclosed
Stock Issuance/Offering (2019): $161.8M backed by Undisclosed
Key Investors in WAVE Life Sciences
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools. RA Capital aims to partner with innovators to bring ideas from the lab to the clinic, ultimately improving patient lives.
Foresite Capital
Foresite Capital is a multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data. Their mission is to address significant unmet needs in healthcare by funding visionary businesses at various stages of their development.
Jennison Associates
Founded in 1969, Jennison Associates offers a range of equity and fixed income investment services across distribution channels. The firm is headquartered in New York, NY.
What's next for WAVE Life Sciences?
The substantial capital raised, including a major strategic investment, positions WAVE Life Sciences for accelerated growth and the advancement of its pipeline. This financing is expected to fuel further research and development, clinical trials, and the scaling of its drug discovery and development platform. The company's trajectory suggests a focus on translating its innovative oligonucleotide technology into tangible therapeutic solutions for patients.
See full WAVE Life Sciences company page
